Cell & Gene Insights Fast Facts: Is Bigger Better in Viral Vector Manufacturing?

Cell & gene therapy (C&GT) is complex, expensive and lacks standardization.

How do you effectively evaluate and make informed decisions to identify a winning viral vector production strategy to improve the accessibility & affordability of C&GT?

We are thrilled to announce our Fast Facts video with Cell & Gene Insights, where our expert Andrea Vervoort, Technical Lead, breaks down key cost drivers of AAV manufacturing and the commercial impacts of incorporating Virica’s Viral Sanitizers (VSE^TM) using Biopharm’s BioSolve Bioprocess modelling.

Click here to view our latest bioprocess modelling data in a Fast Facts video on Cell & Gene Insights!